4th Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$173,210
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 19, 2016 $173,210 Replaced
4th Quarter - Amendment Jan 19, 2016 $263,210 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2 (114th), H.R. 6 (114th), S.Con.Res. 11 (114th), H.Con.Res. 27 (114th)

Budget/Appropriations BUD

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.Con.Res. 27 (114th), S.Con.Res. 11 (114th), H.R. 2 (114th), H.R. 6 (114th)

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 2 (114th), H.R. 6 (114th), H.Con.Res. 27 (114th), S.Con.Res. 11 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.